CELC
Price
$9.32
Change
-$0.79 (-7.81%)
Updated
Apr 1, 04:59 PM (EDT)
Capitalization
344.93M
47 days until earnings call
PRME
Price
$1.78
Change
-$0.21 (-10.55%)
Updated
Apr 1, 04:59 PM (EDT)
Capitalization
234.12M
37 days until earnings call
Ad is loading...

CELC vs PRME

Header iconCELC vs PRME Comparison
Open Charts CELC vs PRMEBanner chart's image
Celcuity
Price$9.32
Change-$0.79 (-7.81%)
Volume$10.2K
Capitalization344.93M
Prime Medicine
Price$1.78
Change-$0.21 (-10.55%)
Volume$20.26K
Capitalization234.12M
CELC vs PRME Comparison Chart
Loading...
CELC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PRME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CELC vs. PRME commentary
Apr 02, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CELC is a StrongBuy and PRME is a Buy.

Ad is loading...
COMPARISON
Comparison
Apr 02, 2025
Stock price -- (CELC: $10.11 vs. PRME: $1.99)
Brand notoriety: CELC and PRME are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CELC: 206% vs. PRME: 231%
Market capitalization -- CELC: $344.93M vs. PRME: $234.12M
CELC [@Biotechnology] is valued at $344.93M. PRME’s [@Biotechnology] market capitalization is $234.12M. The market cap for tickers in the [@Biotechnology] industry ranges from $302.51B to $0. The average market capitalization across the [@Biotechnology] industry is $2.22B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CELC’s FA Score shows that 0 FA rating(s) are green whilePRME’s FA Score has 0 green FA rating(s).

  • CELC’s FA Score: 0 green, 5 red.
  • PRME’s FA Score: 0 green, 5 red.
According to our system of comparison, CELC is a better buy in the long-term than PRME.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CELC’s TA Score shows that 5 TA indicator(s) are bullish while PRME’s TA Score has 5 bullish TA indicator(s).

  • CELC’s TA Score: 5 bullish, 5 bearish.
  • PRME’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, PRME is a better buy in the short-term than CELC.

Price Growth

CELC (@Biotechnology) experienced а -6.73% price change this week, while PRME (@Biotechnology) price change was -1.97% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -9.07%. For the same industry, the average monthly price growth was -13.26%, and the average quarterly price growth was -12.25%.

Reported Earning Dates

CELC is expected to report earnings on May 19, 2025.

PRME is expected to report earnings on May 09, 2025.

Industries' Descriptions

@Biotechnology (-9.07% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CELC($345M) has a higher market cap than PRME($234M). CELC YTD gains are higher at: -22.765 vs. PRME (-31.849). CELC has higher annual earnings (EBITDA): -85.45M vs. PRME (-196.34M). CELC has more cash in the bank: 264M vs. PRME (190M). PRME has less debt than CELC: PRME (40.8M) vs CELC (97.2M). PRME has higher revenues than CELC: PRME (2.98M) vs CELC (0).
CELCPRMECELC / PRME
Capitalization345M234M147%
EBITDA-85.45M-196.34M44%
Gain YTD-22.765-31.84971%
P/E RatioN/AN/A-
Revenue02.98M-
Total Cash264M190M139%
Total Debt97.2M40.8M238%
FUNDAMENTALS RATINGS
CELC vs PRME: Fundamental Ratings
CELC
PRME
OUTLOOK RATING
1..100
1618
VALUATION
overvalued / fair valued / undervalued
1..100
39
Fair valued
47
Fair valued
PROFIT vs RISK RATING
1..100
85100
SMR RATING
1..100
9899
PRICE GROWTH RATING
1..100
6492
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CELC's Valuation (39) in the Miscellaneous Commercial Services industry is in the same range as PRME (47) in the null industry. This means that CELC’s stock grew similarly to PRME’s over the last 12 months.

CELC's Profit vs Risk Rating (85) in the Miscellaneous Commercial Services industry is in the same range as PRME (100) in the null industry. This means that CELC’s stock grew similarly to PRME’s over the last 12 months.

CELC's SMR Rating (98) in the Miscellaneous Commercial Services industry is in the same range as PRME (99) in the null industry. This means that CELC’s stock grew similarly to PRME’s over the last 12 months.

CELC's Price Growth Rating (64) in the Miscellaneous Commercial Services industry is in the same range as PRME (92) in the null industry. This means that CELC’s stock grew similarly to PRME’s over the last 12 months.

CELC's P/E Growth Rating (100) in the Miscellaneous Commercial Services industry is in the same range as PRME (100) in the null industry. This means that CELC’s stock grew similarly to PRME’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CELCPRME
RSI
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
88%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
84%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
82%
MACD
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 2 days ago
83%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
87%
Advances
ODDS (%)
Bullish Trend 9 days ago
83%
Bullish Trend 13 days ago
78%
Declines
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 22 days ago
88%
BollingerBands
ODDS (%)
Bullish Trend 7 days ago
88%
N/A
Aroon
ODDS (%)
Bullish Trend 7 days ago
88%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
CELC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PRME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
VADRX69.77N/A
N/A
Invesco Equally-Wtd S&P 500 R
GGRCX13.18N/A
N/A
Goldman Sachs Strategic Growth C
DQIYX29.84N/A
N/A
BNY Mellon Equity Income Fund Y
ISGDX12.01N/A
N/A
Columbia Integrated Small Cap Gr A
ARAFX10.78N/A
N/A
Aristotle International Eq A

CELC and

Correlation & Price change

A.I.dvisor indicates that over the last year, CELC has been loosely correlated with ABOS. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if CELC jumps, then ABOS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CELC
1D Price
Change %
CELC100%
-1.27%
ABOS - CELC
43%
Loosely correlated
-7.56%
PRME - CELC
43%
Loosely correlated
N/A
CLDX - CELC
41%
Loosely correlated
-8.93%
CRNX - CELC
41%
Loosely correlated
-3.43%
VTGN - CELC
40%
Loosely correlated
-3.47%
More

PRME and

Correlation & Price change

A.I.dvisor indicates that over the last year, PRME has been loosely correlated with CRSP. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if PRME jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PRME
1D Price
Change %
PRME100%
N/A
CRSP - PRME
64%
Loosely correlated
-8.00%
BEAM - PRME
57%
Loosely correlated
-12.07%
RXRX - PRME
56%
Loosely correlated
-8.95%
NTLA - PRME
55%
Loosely correlated
-11.90%
ABCL - PRME
51%
Loosely correlated
-3.46%
More